for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DURECT Corporation

DRRX.OQ

Latest Trade

1.91USD

Change

0.02(+1.06%)

Volume

102,679

Today's Range

1.86

 - 

1.93

52 Week Range

0.48

 - 

2.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.89
Open
1.89
Volume
102,679
3M AVG Volume
16.47
Today's High
1.93
Today's Low
1.86
52 Week High
2.45
52 Week Low
0.48
Shares Out (MIL)
192.36
Market Cap (MIL)
363.56
Forward P/E
-16.61
Dividend (Yield %)
--

Latest Developments

More

Durect Corporation Announces Positive Results From Trial Of Dur-928 In Alcoholic Hepatitis Patients

Durect Reports Q3 Revenue of $10.8 Million

Durect Corp's NASH Trial On Schedule To Be Completed In First Half Of 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Industry

Biotechnology & Drugs

Contact Info

10260 Bubb Rd

+1.408.7771417

http://www.durect.com

Executive Leadership

David R. Hoffmann

Independent Chairman of the Board

James E. Brown

President, Chief Executive Officer and Director

Michael H. Arenberg

Chief Financial Officer

Simon X. Benito

Independent Director

Terrence F. Blaschke

Independent Director

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.260

2017

-0.220

2018

-0.160

2019(E)

-0.110
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.15
Price To Book (MRQ)
16.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
95.21
LT Debt To Equity (MRQ)
81.66
Return on Investment (TTM)
-54.80
Return on Equity (TTM)
-32.59

Latest News

Latest News

BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz

* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)

BRIEF-Durect Corporation Q1 Loss Per Share $0.05

* DURECT CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Durect Announces FDA Advisory Committee Meeting For Remoxy Er

* DURECT ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY® ER

BRIEF-Durect Corporation Qtrly Earnings Per Share ‍$0.05​

* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND UPDATE OF PROGRAMS

BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928

* DURECT CORP SAYS COMMENCED PATIENT DOSING IN A PHASE 2A CLINICAL TRIAL OF DUR-928 IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) - SEC FILING

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

BRIEF-Indivior says ‍durect, co sign $17.5 mln patent purchase deal

* DURECT AND INDIVIOR PLC SIGN A $17.5 MILLION PATENT PURCHASE AGREEMENT

BRIEF-Durect appoints Myriam Theeuwes as senior vice president of clinical development

* Durect appoints Dr. Myriam Theeuwes as senior vice president, clinical development Source text for Eikon: Further company coverage:

BRIEF-Durect Q2 loss per share $0.07

* Durect Corporation announces second quarter 2017 financial results and provides corporate update

BRIEF-Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

* Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

BRIEF-Zogenix and Durect Corp enter into termination agreement

* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing

BRIEF-Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​

* Durect - on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014

BRIEF-Durect completes enrollment in persist, phase 3 trial for Posimir

* Durect completes enrollment in Persist, phase 3 trial for Posimir

BRIEF-Durect's collaboration with Sandoz clears HSR review

* Durect's collaboration with Sandoz clears Hart-Scott-Rodino review and is effective

BRIEF-Durect Corp, Sandoz AG sign U.S. development and commercialization agreement for posimir

* Durect Corp - co and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for U.S. for posimir

BRIEF-Durect Q1 revenue $4.6 million

* Durect Corporation announces first quarter 2017 financial results and provides corporate update

CORRECTED-Durect, Novartis' Sandoz ink deal to develop non-opioid pain drug

Durect Corp said on Monday it signed an up to $293 million deal with Swiss drugmaker Novartis AG's Sandoz unit to develop and market Durect's experimental non-opioid pain relief therapy, posimir, in the United States.

BRIEF-Durect and Sandoz signs a $293 mln development and commercialization agreement for Posimir

* Durect and Sandoz have signed a $293 million development and commercialization agreement for Posimir (saber-bupivacaine) covering the United States

BRIEF-Durect presents data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

* Durect announces presentation of data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up